Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022
10 nov. 2022 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company’s ongoing, multi-cohort, Phase 1b/2 study of the combination therapy of cancer...
Insights on the Rare Diseases Treatment Global Market to 2028 - Players Include AbbVie, F. Hoffmann-La Roche, Bayer, Novartis and Merck
10 nov. 2022 07h03 HE
|
Research and Markets
Dublin, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The "Global Rare Diseases Treatment Market Size, Share & Industry Trends Analysis Report By Distribution Channel (Specialty Pharmacy, Hospital Pharmacy,...
Global Synthetic Small Molecule API Market Report 2022: Featuring Merck, Viatris, Cipla, Teva, Sun Pharmaceuticals & More
07 nov. 2022 04h48 HE
|
Research and Markets
Dublin, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The "Global Synthetic Small Molecule API Market Size, Share & Industry Trends Analysis Report by Manufacturer, Application, Regional Outlook and...
Provectus Biopharmaceuticals Announces World Health Organization Selection of “Rose Bengal Sodium” as International Nonproprietary Name for Active Pharmaceutical Ingredient
02 nov. 2022 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) has...
Pharma R&D Outsourcing Global Market Report 2022: Increasing Collaboration and partnership among CROs and Stakeholders Drives Growth
27 oct. 2022 08h13 HE
|
Research and Markets
Dublin, Oct. 27, 2022 (GLOBE NEWSWIRE) -- The "Pharma R&D Outsourcing Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.In a world of...
Provectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammation
25 oct. 2022 06h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with James G. Krueger, MD, PhD, Co-director,...
Societal CDMO Announces Signing of Multiple New CDMO Service Agreements
20 oct. 2022 07h00 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving...
Societal CDMO Reports Inducement Grants for New Staff
06 oct. 2022 16h05 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving...
Outlook on the Antibody Drug Conjugates Global Market to 2027 - by Component, Target, Application, End-user and Region
29 sept. 2022 08h38 HE
|
Research and Markets
Dublin, Sept. 29, 2022 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Global PD-1/PDL-1 Inhibitor Market Report 2022: Increase in PD-1/PDL-1 Inhibitor Based Combination Regimens Fueling Sector
21 sept. 2022 07h53 HE
|
Research and Markets
Dublin, Sept. 21, 2022 (GLOBE NEWSWIRE) -- The "PD-1/PDL-1 Inhibitor Market - A Global and Regional Analysis: Focus on Epidemiology, Product, and Region - Analysis and Forecast, 2022-2032" report...